ESTRELLA IMMUNOPHARMA, INC. Repayments of Related Party Debt
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Repayments of Related Party Debt of $708.60 thousand for the 6-month period ending 2024-12-31, per its 10-KT filed 2025-03-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfRelatedPartyDebt · last filed 2025-03-25
- ESTRELLA IMMUNOPHARMA, INC. repayments of related party debt for the quarter ending 2024-12-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. repayments of related party debt for the quarter ending 2024-09-30 was $708.60K.
- ESTRELLA IMMUNOPHARMA, INC. repayments of related party debt for the quarter ending 2024-06-30 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. repayments of related party debt for the quarter ending 2021-12-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. repayments of related party debt for fiscal 2024 was $708.60K.
- ESTRELLA IMMUNOPHARMA, INC. repayments of related party debt for fiscal 2021 was $300.00K.
| Period end | Repayments of Related Party Debt | Repayments of Related Party Debt 3 month | Repayments of Related Party Debt 6 month | Repayments of Related Party Debt 9 month | Repayments of Related Party Debt 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-KT 6 month − 10-Q 3 month · filed 2025-03-25 | $708.60K 10-KT · filed 2025-03-25 | $708.60K derived: sum of 3 quarters · filed 2025-03-25 | ||
| 2024-09-30 | $708.60K 10-Q · filed 2024-11-14 | $708.60K derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2024-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-27 | $708.60K 10-K · filed 2024-09-27 | |||
| 2024-03-31 | $708.60K 10-Q · filed 2024-05-15 | ||||
| 2023-09-29 | $708.60K 10-Q · filed 2024-02-14 | $708.60K 10-Q · filed 2023-11-20 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $180.00K derived: sum of 2 quarters · filed 2023-03-14 | $300.00K 10-K · filed 2023-03-14 | ||
| 2021-09-30 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $300.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $120.00K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |